NASDAQ:EPRX Eupraxia Pharmaceuticals (EPRX) Stock Price, News & Analysis $5.46 +0.08 (+1.39%) As of 07/3/2025 03:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Eupraxia Pharmaceuticals Stock (NASDAQ:EPRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get EPRX alerts:Sign Up Key Stats Today's Range$5.30▼$5.7450-Day Range$3.79▼$5.8452-Week Range$2.20▼$6.20Volume8,647 shsAverage Volume13,337 shsMarket Capitalization$196.52 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingBuy Company Overview Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC. Read More Eupraxia Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreEPRX MarketRank™: Eupraxia Pharmaceuticals scored higher than 49% of companies evaluated by MarketBeat, and ranked 1663rd out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingEupraxia Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEupraxia Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Eupraxia Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Eupraxia Pharmaceuticals are expected to grow in the coming year, from ($0.67) to ($0.60) per share.Read more about Eupraxia Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.62% of the float of Eupraxia Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEupraxia Pharmaceuticals has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.Change versus previous monthShort interest in Eupraxia Pharmaceuticals has recently increased by 0.17%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEupraxia Pharmaceuticals does not currently pay a dividend.Dividend GrowthEupraxia Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.62% of the float of Eupraxia Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEupraxia Pharmaceuticals has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.Change versus previous monthShort interest in Eupraxia Pharmaceuticals has recently increased by 0.17%, indicating that investor sentiment is decreasing. News and Social Media2.8 / 5News Sentiment1.03 News SentimentEupraxia Pharmaceuticals has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Eupraxia Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for EPRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eupraxia Pharmaceuticals insiders have not sold or bought any company stock.Read more about Eupraxia Pharmaceuticals' insider trading history. Receive EPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address EPRX Stock News HeadlinesEupraxia Pharmaceuticals (NASDAQ:EPRX) Research Coverage Started at HC WainwrightJune 29, 2025 | americanbankingnews.comEupraxia Pharmaceuticals Stock Short Interest Report | NASDAQ:EPRX - BenzingaJune 27, 2025 | benzinga.comThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.July 4 at 2:00 AM | Crypto Swap Profits (Ad)Eupraxia Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:EPRX - BenzingaJune 26, 2025 | benzinga.comEupraxia Pharma director buys as stock tests top of rangeJune 26, 2025 | theglobeandmail.comHC Wainwright & Co. Initiates Coverage of Eupraxia Pharmaceuticals (EPRX) with Buy RecommendationJune 26, 2025 | msn.comThis NRG Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayJune 26, 2025 | benzinga.comEupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of ShareholdersJune 2, 2025 | globenewswire.comSee More Headlines EPRX Stock Analysis - Frequently Asked Questions How have EPRX shares performed this year? Eupraxia Pharmaceuticals' stock was trading at $3.17 at the beginning of the year. Since then, EPRX stock has increased by 72.4% and is now trading at $5.4650. How were Eupraxia Pharmaceuticals' earnings last quarter? Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) released its quarterly earnings data on Tuesday, May, 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.02. How do I buy shares of Eupraxia Pharmaceuticals? Shares of EPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eupraxia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eupraxia Pharmaceuticals investors own include Aeterna Zentaris (AEZS), BlackBerry (BB), Bausch Health Cos (BHC), Bitfarms (BITF), Ballard Power Systems (BLDP), Cardiol Therapeutics (CRDL) and Fury Gold Mines (FURY). Company Calendar Last Earnings5/06/2025Today7/04/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EPRX Previous SymbolNASDAQ:EPRX CIK1581178 Webwww.eupraxiapharma.com Phone250-590-3968FaxN/AEmployees29Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$12.00 Low Stock Price Target$9.00 Potential Upside/Downside+101.3%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$25.50 million Net MarginsN/A Pretax MarginN/A Return on Equity-367.73% Return on Assets-112.23% Debt Debt-to-Equity RatioN/A Current Ratio11.10 Quick Ratio11.10 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares35,960,000Free FloatN/AMarket Cap$196.52 million OptionableN/A Beta1.55 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:EPRX) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.